8-K: OpGen Faces Delisting Threat After Failing to File Annual Report, Adding to Existing Bid Price Non-Compliance

OpGen, Inc. received a notice from Nasdaq for failing to file its annual report, adding to existing concerns about its share price and increasing the risk of delisting.

Summary

• OpGen, Inc. has received a notice from Nasdaq stating that the company is not in compliance with listing rules due to the failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
• This non-compliance is in addition to a previous notice regarding the company's failure to maintain a minimum bid price of $1.00 per share.
• The company has until June 3, 2024, to regain compliance with both listing rules, including filing the overdue 10-K report.
• The Nasdaq Hearings Panel will consider the delinquent Form 10-K in connection with its prior grant of an additional period to regain compliance.
• The company is working to finalize the Form 10-K and plans to file it as soon as practicable, but there is no guarantee of the filing date or the final decision of the Nasdaq Hearings Panel regarding delisting.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the delisting threat and the company's failure to meet financial reporting deadlines. The company is facing significant challenges and uncertainty.

Positives

• The company has been granted an additional period until June 3, 2024, to regain compliance with Nasdaq listing rules.
• OpGen is working diligently to finalize the Form 10-K and plans to file it as soon as practicable.

Negatives

• OpGen is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Annual Report on Form 10-K.
• The company is also not in compliance with Nasdaq Listing Rule 5550(a)(2) for failing to maintain a minimum bid price of $1.00 per share.
• There is no assurance as to the definitive date on which the Form 10-K will be filed or the final decision of the Nasdaq Hearings Panel regarding a delisting of the company's securities.

Risks

• The company may not be able to regain compliance with Nasdaq listing rules by June 3, 2024.
• Failure to file the Form 10-K by the deadline could result in the delisting of the company's securities from Nasdaq.
• There is a risk that the company's financial reporting process may face further delays.
• The company's ability to continue to finance its business and operations is uncertain.

Future Outlook

The company plans to file its Form 10-K as soon as practicable and is working to regain compliance with Nasdaq listing rules by June 3, 2024, but there is no assurance of success.

Management Comments

• The company plans to file its Form 10-K as soon as practicable.
• The company is working diligently to finalize the Form 10-K.

Industry Context

This announcement highlights the challenges faced by smaller biotech companies in maintaining compliance with listing requirements, particularly in a volatile market environment. Delays in financial reporting and low share prices are common issues that can lead to delisting.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining minimum bid prices and timely financial reporting.
• Companies like Aytu BioScience and Diffusion Pharmaceuticals have also faced delisting notices from Nasdaq in recent years.
• The requirement to maintain a $1.00 minimum bid price is a common hurdle for companies with volatile stock prices.
• The delay in filing the 10-K is a significant issue, as timely financial reporting is a key requirement for maintaining a listing on Nasdaq.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment.
• Employees may experience uncertainty about the company's future.
• Customers and suppliers may be concerned about the company's ability to continue operations.

Next Steps

• The company needs to finalize and file its Form 10-K as soon as practicable.
• The company must regain compliance with Nasdaq listing rules by June 3, 2024.
• The Nasdaq Hearings Panel will review the company's plan to cure the delinquency.

Key Dates

Keywords

delisting, Nasdaq, non-compliance, Form 10-K, minimum bid price, financial reporting, OPGN